- Tagliazucchi, Lorenzo
- Pinetti, Diego
- Genovese, Filippo
- Malpezzi, Giulia
- Perea Martínez, Ana
- Manzano, José Ignacio
- García-Hernández, Raquel
- Cole, Alexander R.
- Kwon, Ba Reum
- Aiello, Daniele
- Brooks, Bryan W.
- Thoré, Eli S. J.
- Bertram, Michael G.
- Gamarro, Francisco
- Costi, Maria Paola
Published as part of ACS Infectious Diseases virtual special issue “One Health and Vector Borne Parasitic Diseases”., Recent efforts in the study of vector-borne parasitic diseases (VBPDs) have emphasized an increased consideration for preventing drug resistance and promoting the environmental safety of drugs, from the beginning of the drug discovery pipeline. The intensive use of the few available antileishmanial drugs has led to the spreading of hyper-resistant Leishmania infantum strains, resulting in a chronic burden of the disease. In the present work, we have investigated the biochemical mechanisms of resistance to antimonials, paromomycin, and miltefosine in three drug-resistant parasitic strains from human clinical isolates, using a whole-cell mass spectrometry proteomics approach. We identified 14 differentially expressed proteins that were validated with their transcripts. Next, we employed functional association networks to identify parasite-specific proteins as potential targets for novel drug discovery studies. We used SeqAPASS analysis to predict susceptibility based on the evolutionary conservation of protein drug targets across species. MATH-domain-containing protein, adenosine triphosphate (ATP)-binding cassette B2, histone H4, calpain-like cysteine peptidase, and trypanothione reductase emerged as top candidates. Overall, this work identifies new biological targets for designing drugs to prevent the development of Leishmania drug resistance, while aligning with One Health principles that emphasize the interconnected health of people, animals, and ecosystems., We thank Dr. F. Javier Moreno from the WHO Collaborating Centre for Leishmaniasis, Instituto de Salud Carlos III (ISCIII), for providing L. infantum lines LLM2070, LLM2165, LLM2255, and LLM2221, isolated from HIV-positive patients with visceral leishmaniasis and TF, and the paromomycin-resistant L. infantum line LEM2126 (L2126) used in this study. Also, we thank Dr. Laurence Lachaud from the Centre National de Référence des Leishmanioses, Université Montpellier (Montpellier, France), for providing the drug-resistant L. infantum lines used in this work: LEM3323 (L3323) and LEM5159 (L5159), which are SbIII- and MIL-resistant lines, respectively. The authors acknowledge Dr. Sotiris Ouzounis for critically reading the manuscript and providing suggestions for the statistics part. The authors also thank Dr. Stefania Ferrari for annotating L. infantum database for protein search, which was obtained from SwissProt (L. infantum entry, exported in FASTA format, updated January 2023, updates are ongoing). The authors acknowledge the “Fondazione Cassa di Risparmio di Modena” for funding the UHPLC-ESI-HRMS Q-Exactive system at the Centro Interdipartimentale Grandi Strumenti (CIGS) of the University of Modena and Reggio Emilia., This work was inspired and developed within the COST Action “OneHealthdrugs” CA21111. Thanks are due to Grant RTI2018-097210-B-100 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A Way of Making Europe” awarded to F. Gamarro., Peer reviewed